The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007

Author： Lichtenberg Frank  

Publisher： Springer Publishing Company

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.14, Iss.1, 2013-02, pp. : 41-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

MORTALITY FROM DISEASES ASSOCIATED WITH SMOKING: UNITED STATES, 1950–64

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 15, Iss. 5, 1967-05 ,pp. : 504-506

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of inhibitors on hemophilia a mortality in the United States

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : 400-405

John Wiley & Sons Inc

Access to resources Recommend Favorite

Premature Mortality: A Neglected Outcome in Rheumatic Diseases?

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 8, 2015-08 ,pp. : 1043-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Decrease in Socioeconomic Differences in Mortality from 1920 to 2000 in the United States and England

By Rothstein William G.  

Journal of the History of Medicine and Allied Sciences, Vol. 67, Iss. 4, 2012-10 ,pp. : 515-552

Oxford University Press

Access to resources Recommend Favorite

Rare Diseases and Orphan Drugs: A comprehensive approach of strategic perspectives

By Hansen Jan-C閐ric  

Journal of Communication In Healthcare, Vol. 5, Iss. 4, 2012-12 ,pp. : 199-219

Maney Publishing

Access to resources Recommend Favorite